Study guide
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management
Key Takeaways Explain This Topic AI
Hypertensive disorders of pregnancy are categorized into four core entities: chronic hypertension (pre-dating pregnancy or diagnosed before 20 weeks), gestational hypertension (new onset BP >=140/90 after 20 weeks without proteinuria), preeclampsia-eclampsia, and chronic hypertension with superimposed preeclampsia.
Preeclampsia diagnosis requires new-onset hypertension (>=140/90 mmHg on two occasions at least 4 hours apart) after 20 weeks gestation plus proteinuria (>=300 mg/24-hour urine, UPCR >=0.3, or dipstick 2+), OR in the absence of proteinuria, any new severe feature.
Severe features include systolic BP >=160 or diastolic BP >=110 mmHg, thrombocytopenia (platelets <100,000/mcL), impaired liver function (AST/ALT >2x normal) or severe persistent RUQ/epigastric pain, progressive renal insufficiency (serum creatinine >1.1 mg/dL or doubling), pulmonary edema, or new visual/cerebral disturbances.
Seizure prophylaxis requires magnesium sulfate (4–6 g IV loading dose over 20–30 minutes, followed by 1–2 g/hr continuous infusion); therapeutic range is 4.8–8.4 mg/dL (4–7 mEq/L), monitored via patellar reflexes, respiratory rate (>=12/min), and urine output (>=30 mL/hr), with calcium gluconate 1 g IV ready for toxicity reversal.
Acute severe hypertension (BP >=160/110 mmHg) is a hypertensive emergency requiring intervention within 30–60 minutes using IV labetalol, IV hydralazine, or oral immediate-release nifedipine, while low-dose aspirin 81 mg daily, started at 12–28 weeks and ideally before 16 weeks, is the U.S. standard for preeclampsia prevention in at-risk patients.
Last updated: October 2026
Classification of Hypertensive Disorders in Pregnancy
Hypertensive disorders of pregnancy encompass a spectrum of vascular and multisystem pathologies. Precise classification dictates maternal-fetal surveillance, pharmacologic thresholds, and timing of delivery.
1. Chronic Hypertension
Diagnostic Criteria: Blood pressure (BP) ≥140 mmHg systolic and/or ≥90 mmHg diastolic that pre-dates pregnancy, is diagnosed before 20 weeks gestation , or persists longer than 12 weeks postpartum .
Clinical Significance: Carries a 20% to 25% risk of developing superimposed preeclampsia, intrauterine fetal growth restriction (FGR), and placental abruption.
2. Gestational Hypertension
Diagnostic Criteria: New-onset systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg documented on two occasions at least 4 hours apart after 20 weeks gestation in a previously normotensive patient, in the absence of proteinuria or systemic end-organ dysfunction.
Clinical Course: Blood pressure normalizes before 12 weeks postpartum (confirming transient gestational hypertension). If hypertension persists beyond 12 weeks postpartum, the diagnosis is reclassified as chronic hypertension. Up to 50% of women presenting with gestational hypertension eventually develop preeclampsia features.
3. Preeclampsia Without Severe Features
Diagnostic Criteria: New-onset hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg on two occasions at least 4 hours apart after 20 weeks) PLUS proteinuria .
Proteinuria Definitions:
≥ 300 mg per 24-hour urine collection (gold standard).
Urine protein-to-creatinine ratio ( UPCR ) ≥ 0.3 mg/mg.
Urine dipstick protein reading of 2+ (utilized only when quantitative methods are unavailable).
4. Preeclampsia With Severe Features
Diagnosed when preeclampsia exhibits systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg on two occasions at least 4 hours apart (sooner if antihypertensive therapy has been started), OR any of the following new-onset systemic manifestations develops ( even in the complete absence of proteinuria ):
Thrombocytopenia: Platelet count <100,000/mcL .
Impaired Liver Function: Serum transaminases (AST or ALT) elevated to greater than twice the upper limit of normal , or severe persistent right upper quadrant or epigastric pain unresponsive to medication and not accounted for by alternative diagnoses.
Progressive Renal Insufficiency: Serum creatinine >1.1 mg/dL or a doubling of baseline serum creatinine concentration in the absence of pre-existing renal disease.
Pulmonary Edema: Clinical dyspnea, hypoxemia, rales, and radiographic pulmonary congestion.
New-Onset Visual or Cerebral Disturbances: Intractable, severe throbbing headache unresponsive to analgesics, scotomata, photopsia, cortical blindness, or altered mental status.
Important
Under current clinical practice standards, massive proteinuria (>5 g/24 hours) and fetal growth restriction (FGR) are no longer classified as standalone severe features that mandate immediate preterm delivery. However, close antenatal fetal surveillance remains paramount when FGR is present.
5. Chronic Hypertension With Superimposed Preeclampsia
Diagnosed in a woman with pre-existing chronic hypertension who develops new-onset proteinuria after 20 weeks gestation, a sudden refractory acceleration in blood pressure, or any of the systemic severe features (thrombocytopenia, transaminitis, renal impairment, pulmonary edema, or neurological symptoms).
6. Eclampsia
Definition: The onset of new generalized tonic-clonic seizures in a pregnant or postpartum patient with preeclampsia that cannot be attributed to other neurologic causes (e.g., epilepsy, intracranial hemorrhage, infection, or metabolic derangement).
Timing: Approximately 50% of eclamptic events occur antepartum, 25% intrapartum, and 25% postpartum (most within the first 48 hours, though late postpartum eclampsia can occur up to 6 weeks postpartum).
7. HELLP Syndrome
A severe variant of preeclampsia characterized by microvascular endothelial activation, fibrin deposition, platelet consumption, and hepatic microvascular ischemia:
H (Hemolysis): Microangiopathic hemolytic anemia with peripheral smear schistocytes, elevated total bilirubin (≥1.2 mg/dL), low serum haptoglobin, and lactate dehydrogenase ( LDH >600 IU/L ).
EL (Elevated Liver Enzymes): Serum AST or ALT ≥2 times the upper limit of normal .
LP (Low Platelets): Platelet count <100,000/mcL .
- Hypertensive Disorder Onset Window BP Threshold (mmHg) Proteinuria Required? Hallmark Features
- Chronic Hypertension <20 weeks or pre-pregnancy ≥140/90 No Persists >12 weeks postpartum
- Gestational Hypertension >20 weeks gestation ≥140/90 No No end-organ damage; normalizes postpartum
Preeclampsia (without severe) >20 weeks gestation ≥140/90 Yes (or end-organ) Proteinuria ≥300 mg/24h or UPCR ≥0.3
Preeclampsia (with severe) >20 weeks gestation ≥160/110 OR severe feature No Platelets <100k, transaminitis, Cr >1.1, neuro symptoms
- Eclampsia Antepartum, intrapartum, postpartum Variable Variable New generalized tonic-clonic seizures
- HELLP Syndrome >20 weeks or postpartum Variable Variable Hemolysis (LDH >600), AST/ALT >2x, Platelets <100k
- Pharmacotherapy: Seizure Prophylaxis with Magnesium Sulfate
Magnesium sulfate is the definitive, first-line agent for the prevention and treatment of eclamptic seizures. It functions via central nervous system vasodilation, protection of the blood-brain barrier against hydrostatic edema, and competitive antagonism of N-methyl-D-aspartate (NMDA) receptor channels.
Dosing Regimen
Loading Dose: 4 to 6 grams IV diluted in 100 mL normal saline or D5W administered over 20 to 30 minutes .
Maintenance Infusion: 1 to 2 grams per hour continuous IV infusion, maintained throughout labor and continued for 24 hours postpartum or 24 hours after the last seizure.
Therapeutic Serum Level: 4.8 to 8.4 mg/dL (equivalent to 4.0 to 7.0 mEq/L ).
Clinical Monitoring Protocol
Because magnesium is excreted entirely by the kidneys, patients must undergo rigorous, frequent bedside assessments:
Deep Tendon Reflexes (DTRs): Patellar reflexes must be present. Loss of DTRs is the earliest clinical sign of hypermagnesemia, occurring at levels of 9 to 12 mg/dL (7.5–10 mEq/L).
Respiratory Rate: Must be ≥12 breaths per minute . Respiratory depression occurs at levels of 12 to 15 mg/dL (10–12.5 mEq/L).
Urinary Output: Must be maintained at ≥30 mL/hour (or ≥100 mL over 4 hours). If renal output drops, magnesium rapidly accumulates, precipitating toxicity.
Cardiac Conduction Deficits & Arrest: Occur at serum concentrations >15 to 20 mg/dL .
Management of Magnesium Toxicity
If hyporeflexia, respiratory depression, or altered sensorium occurs:
Immediately discontinue the magnesium sulfate infusion.
Administer Calcium Gluconate: 1 gram IV push (10 mL of a 10% solution) slowly over 2 to 3 minutes .
Provide supplemental oxygen and secure the airway if respiratory failure is imminent.
Note
In patients with renal insufficiency (serum creatinine >1.1 mg/dL), administer the standard 4 g loading dose, but reduce the maintenance infusion to 1 g/hour (or monitor serial serum magnesium concentrations every 4 to 6 hours, adjusting the rate accordingly).
Acute Severe Antihypertensive Protocols
Acute-onset, sustained severe hypertension (systolic BP ≥160 mmHg and/or diastolic BP ≥110 mmHg lasting ≥15 minutes) in pregnancy or the puerperium represents a hypertensive emergency. The primary objective is to prevent maternal intracranial hemorrhage, encephalopathy, and cardiovascular collapse. Emergency antihypertensive pharmacotherapy must be initiated within 30 to 60 minutes .
Agent Initial Dose Escalation & Dosing Interval Clinical Pearls & Contraindications
IV Labetalol 20 mg IV bolus over 2 minutes If BP remains ≥160/110 at 10 min, give 40 mg IV ; if still elevated at 20 min, give 80 mg IV ; then 80 mg IV at 30 min (Max: 220–300 mg total). Combined alpha- and beta-blocker. Contraindicated in active asthma, severe sinus bradycardia, heart block >first degree, and decompensated heart failure.
IV Hydralazine 5 to 10 mg IV bolus over 2 minutes If BP remains ≥160/110 at 20 min, administer 10 mg IV ; repeat q20 min as needed (Max: 20–30 mg total). Direct peripheral arteriolar vasodilator. May induce reflex tachycardia, maternal hypotension, and fetal heart rate decelerations.
Oral Nifedipine 10 to 20 mg PO immediate-release If BP remains ≥160/110 at 20–30 min, administer 20 mg PO ; repeat q20–30 min as needed (Max: 180 mg/day). Calcium channel blocker. Excellent oral alternative when IV access is not yet established. Do not administer sublingually (precipitates unpredictable profound hypotension).
- Preeclampsia Prevention & Delivery Timing
- Prevention with Low-Dose Aspirin
Mechanism: Selectively inhibits platelet cyclooxygenase-1 (COX-1), restoring the balance between prothrombotic thromboxane A2 and vasodilatory prostacyclin, promoting physiological trophoblastic invasion.
Dosing & Initiation: 81 mg daily in U.S. guidance (ACOG Committee Opinion 743; USPSTF 2021), started at 12–28 weeks (optimally before 16 weeks) and continued until delivery. Some international guidelines use about 150–162 mg.
Indications:
High Risk (≥1 factor): Prior pregnancy complicated by preeclampsia, chronic hypertension, pregestational type 1 or type 2 diabetes, chronic renal disease, autoimmune disease (systemic lupus erythematosus, antiphospholipid syndrome), or multifetal gestation.
Moderate Risk (≥2 factors): Nulliparity, obesity (pre-pregnancy BMI >30 kg/m²), family history of preeclampsia, advanced maternal age (≥35 years), sociodemographic characteristics, or personal history factors (low birth weight, prior adverse outcome).
Standardized Delivery Timing
Definitive treatment for preeclampsia is delivery of the fetus and placenta. Timing is calibrated to balance maternal systemic risks against neonatal prematurity:
Gestational Hypertension or Preeclampsia WITHOUT Severe Features: Planned delivery at 37 0/7 weeks gestation .
Preeclampsia WITH Severe Features: Delivery at 34 0/7 weeks gestation after stabilization. Expectant management between 24 0/7 and 33 6/7 weeks is considered only at tertiary centers in stable maternal-fetal conditions.
Immediate Delivery (Regardless of Gestational Age): Mandated for maternal instability: refractory acute severe hypertension, eclamptic seizures, pulmonary edema, placental abruption, disseminated intravascular coagulation (DIC), progressive renal failure, or non-reassuring fetal status.